Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjus...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Text |
Language: | unknown |
Published: |
figshare
2019
|
Subjects: | |
Online Access: | https://dx.doi.org/10.6084/m9.figshare.10037333 https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333 |
id |
ftdatacite:10.6084/m9.figshare.10037333 |
---|---|
record_format |
openpolar |
spelling |
ftdatacite:10.6084/m9.figshare.10037333 2023-05-15T16:01:56+02:00 Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Attarian, Shahram Jean-Michel Vallat Magy, Laurent Funalot, Benoît Pierre-Marie Gonnaud Lacour, Arnaud Péréon, Yann Dubourg, Odile Pouget, Jean Micallef, Joëlle Franques, Jérôme Marie-Noëlle Lefebvre Ghorab, Karima Al-Moussawi, Mahmoud Tiffreau, Vincent Preudhomme, Marguerite Magot, Armelle Leclair-Visonneau, Laurène Stojkovic, Tanya Bossi, Laura Lehert, Philippe Gilbert, Walter Bertrand, Viviane Mandel, Jonas Milet, Aude Hajj, Rodolphe Boudiaf, Lamia Scart-Grès, Catherine Nabirotchkin, Serguei Guedj, Mickael Chumakov, Ilya Cohen, Daniel 2019 https://dx.doi.org/10.6084/m9.figshare.10037333 https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333 unknown figshare https://dx.doi.org/10.1186/s13023-016-0463-6 Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 CC-BY Biochemistry Medicine Neuroscience Pharmacology Biotechnology 39999 Chemical Sciences not elsewhere classified FOS Chemical sciences Science Policy Text article-journal Journal contribution ScholarlyArticle 2019 ftdatacite https://doi.org/10.6084/m9.figshare.10037333 https://doi.org/10.1186/s13023-016-0463-6 2021-11-05T12:55:41Z Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman’s rank correlation. P-values are one-tailed. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity; VAS = Visual Analog Scale; CGI = Clinical Global Impression. (DOC 168 kb) Text DML DataCite Metadata Store (German National Library of Science and Technology) Charcot ENVELOPE(139.017,139.017,-69.367,-69.367) |
institution |
Open Polar |
collection |
DataCite Metadata Store (German National Library of Science and Technology) |
op_collection_id |
ftdatacite |
language |
unknown |
topic |
Biochemistry Medicine Neuroscience Pharmacology Biotechnology 39999 Chemical Sciences not elsewhere classified FOS Chemical sciences Science Policy |
spellingShingle |
Biochemistry Medicine Neuroscience Pharmacology Biotechnology 39999 Chemical Sciences not elsewhere classified FOS Chemical sciences Science Policy Attarian, Shahram Jean-Michel Vallat Magy, Laurent Funalot, Benoît Pierre-Marie Gonnaud Lacour, Arnaud Péréon, Yann Dubourg, Odile Pouget, Jean Micallef, Joëlle Franques, Jérôme Marie-Noëlle Lefebvre Ghorab, Karima Al-Moussawi, Mahmoud Tiffreau, Vincent Preudhomme, Marguerite Magot, Armelle Leclair-Visonneau, Laurène Stojkovic, Tanya Bossi, Laura Lehert, Philippe Gilbert, Walter Bertrand, Viviane Mandel, Jonas Milet, Aude Hajj, Rodolphe Boudiaf, Lamia Scart-Grès, Catherine Nabirotchkin, Serguei Guedj, Mickael Chumakov, Ilya Cohen, Daniel Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
topic_facet |
Biochemistry Medicine Neuroscience Pharmacology Biotechnology 39999 Chemical Sciences not elsewhere classified FOS Chemical sciences Science Policy |
description |
Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman’s rank correlation. P-values are one-tailed. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity; VAS = Visual Analog Scale; CGI = Clinical Global Impression. (DOC 168 kb) |
format |
Text |
author |
Attarian, Shahram Jean-Michel Vallat Magy, Laurent Funalot, Benoît Pierre-Marie Gonnaud Lacour, Arnaud Péréon, Yann Dubourg, Odile Pouget, Jean Micallef, Joëlle Franques, Jérôme Marie-Noëlle Lefebvre Ghorab, Karima Al-Moussawi, Mahmoud Tiffreau, Vincent Preudhomme, Marguerite Magot, Armelle Leclair-Visonneau, Laurène Stojkovic, Tanya Bossi, Laura Lehert, Philippe Gilbert, Walter Bertrand, Viviane Mandel, Jonas Milet, Aude Hajj, Rodolphe Boudiaf, Lamia Scart-Grès, Catherine Nabirotchkin, Serguei Guedj, Mickael Chumakov, Ilya Cohen, Daniel |
author_facet |
Attarian, Shahram Jean-Michel Vallat Magy, Laurent Funalot, Benoît Pierre-Marie Gonnaud Lacour, Arnaud Péréon, Yann Dubourg, Odile Pouget, Jean Micallef, Joëlle Franques, Jérôme Marie-Noëlle Lefebvre Ghorab, Karima Al-Moussawi, Mahmoud Tiffreau, Vincent Preudhomme, Marguerite Magot, Armelle Leclair-Visonneau, Laurène Stojkovic, Tanya Bossi, Laura Lehert, Philippe Gilbert, Walter Bertrand, Viviane Mandel, Jonas Milet, Aude Hajj, Rodolphe Boudiaf, Lamia Scart-Grès, Catherine Nabirotchkin, Serguei Guedj, Mickael Chumakov, Ilya Cohen, Daniel |
author_sort |
Attarian, Shahram |
title |
Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
title_short |
Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
title_full |
Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
title_fullStr |
Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
title_full_unstemmed |
Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
title_sort |
additional file 4: table s4. of erratum to: an exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (pxt3003) in patients with charcot-marie-tooth disease type 1a |
publisher |
figshare |
publishDate |
2019 |
url |
https://dx.doi.org/10.6084/m9.figshare.10037333 https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333 |
long_lat |
ENVELOPE(139.017,139.017,-69.367,-69.367) |
geographic |
Charcot |
geographic_facet |
Charcot |
genre |
DML |
genre_facet |
DML |
op_relation |
https://dx.doi.org/10.1186/s13023-016-0463-6 |
op_rights |
Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.6084/m9.figshare.10037333 https://doi.org/10.1186/s13023-016-0463-6 |
_version_ |
1766397604969578496 |